ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”

ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced that it has received final approval from The Nasdaq Capital Market LLC (“Nasdaq”) to list its common shares (the “Common Shares”) on Nasdaq. The Company’s Common Shares will begin trading on Friday, July 8th, 2022, under the symbol “PMN”.

 

The Company’s Common Shares will continue to trade on the Toronto Stock Exchange (TSX) under the same symbol “PMN” (its current symbol). Concurrent with the listing of ProMIS’ Common Shares on Nasdaq, the Common Shares will cease to be quoted on the OTCQB.

 

Eugene Williams, Chairman and CEO of ProMIS, said, “The listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly traded company.  Nasdaq is the premier global stock exchange for life science and biotechnology companies.  We believe this listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value.  I would like to thank our shareholders for their support, as well as everyone whose hard work has resulted in making ProMIS a member of the Nasdaq exchange.  This transformative step will help facilitate the continued advancement of our pipeline of differentiated therapies targeting misfolded proteins in Alzheimer’s, ALS, and other diseases with significant unmet need.”

 

ProMIS Neurosciences Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform – ProMIS™ and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and PD.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the Toronto Stock Exchange under the symbol PMN.

 

www.promisneurosciences.com

 

Twitter and LinkedIn

 

Hot this week

The European Magazine Announces The Winners Of Its 2024 Awards

The European is proud to announce the final full...

Capital on Tap launches business savings accounts in strategic expansion 

Capital on Tap, a leading all-in-one small business credit card and...

Israel Renews Western Journalist Ban In Gaza To Limit Global Condemnation

Israel frequently claims to be the only democracy in...

Israel Kills Over 100 Palestinians Since Ceasefire, Prompting Hamas to Halt Prisoner Releases

Since the ceasefire in Gaza and the West Bank...

Robert J. Smith, MFA’s latest release tops legends; Adam Smith, w. Edwards Deming, and Edward Bernays

Robert J. Smith, The Father of Factual Storytelling, has...

Topics

The European Magazine Announces The Winners Of Its 2024 Awards

The European is proud to announce the final full...

Capital on Tap launches business savings accounts in strategic expansion 

Capital on Tap, a leading all-in-one small business credit card and...

Israel Renews Western Journalist Ban In Gaza To Limit Global Condemnation

Israel frequently claims to be the only democracy in...

British Journalist Sparks Outrage Over Anti-Palestinian Comments Amid Gaza Genocide

A growing controversy has erupted over incendiary remarks made...

When Israel turned on the US, showing we’re all ‘Amalek’ in the end

In 2023, Israeli PM Netanyahu referenced the biblical command...

British Journalist Richard Medhurst Raided in Austria For Gaza Genocide Coverage

Independent journalist Richard Medhurst was detained by Austrian authorities...

Related Articles

Popular Categories

spot_imgspot_img